{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:29Z","timestamp":1787026949076,"version":"build-2736575974"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Microsatellite instability-high (MSI-H) is an established biomarker of response to immune checkpoint inhibitors, though it is rarely observed in pancreatic ductal adenocarcinoma (PDAC). Even less common is the emergence of MSI-H during the disease course, particularly when identified through liquid biopsy. Such findings raise important considerations regarding tumor evolution, assay concordance, and therapeutic decision-making.<\/jats:p>\n <\/jats:sec>\n \n Case Presentation<\/jats:title>\n \n We report the case of a 76-year-old woman with borderline resectable PDAC who received first-line chemotherapy for nearly 20 months, maintaining excellent performance status and disease control. Upon clinical and biochemical progression, liquid biopsy using Guardant360 CDx revealed MSI-H status and a TP53 H214fs mutation, both absent in her initial molecular profile. A concurrent FoundationOne\n \u00ae<\/jats:sup>\n Liquid CDx analysis detected a high circulating tumor DNA fraction but reported the tumor as microsatellite stable, highlighting a discordance in MSI classification across platforms. Given her favorable clinical condition and emerging molecular findings, pembrolizumab was initiated. The patient experienced sustained clinical benefit and radiographic stability for 13 months before progressing with peritoneal carcinomatosis and ascites.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This case illustrates the potential emergence of MSI-H during the disease course of PDAC and highlights the clinical value of repeat molecular profiling at progression. It also highlights clinically relevant discrepancies in MSI detection between liquid biopsy platforms and supports the role of immunotherapy in selected patients with evolving molecular features.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1659656","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:39:09Z","timestamp":1776055149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: immunotherapy response in pancreatic cancer after MSI-H emerged post-chemotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Kareem","family":"Gharaybeh","sequence":"first","affiliation":[{"name":"Stratford Preparatory High School, San Jose","place":["San Jose, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Khalidi","sequence":"additional","affiliation":[{"name":"Al Khalidi Hospital and Medical Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Al-Sukhun","sequence":"additional","affiliation":[{"name":"Al Hyatt Oncology Practice.","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt166","article-title":"Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials","volume":"24","author":"Rahma","year":"2013","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0653-y","article-title":"A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma","volume":"62","author":"Reni","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1007\/s12029-020-00573-y","article-title":"Metastatic pancreatic cancer second-line treatment options: is the difference only in cost","volume":"53","author":"Yildirim","year":"2022","journal-title":"J Gastrointest Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s40425-018-0448-1","article-title":"Acquired resistance to immunotherapy in MMR-D pancreatic cancer","volume":"6","author":"Hu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3332\/ecancer.2023.1535","article-title":"Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma","volume":"17","author":"Al-Sukhun","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/path.6279","article-title":"Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy","volume":"263","author":"Geurts","year":"2024","journal-title":"J Pathol"},{"key":"B11","article-title":"Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients","volume":"7","author":"Fonseca","year":"2005","journal-title":"Breast Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:39:35Z","timestamp":1776055175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1659656"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1659656","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1659656"}}